NICE says Merck head and neck cancer drug Erbitux is not cost-effective

1 November 2016

The National Institute for Health and Care Excellence (NICE), in draft guidance released this morning, said that head and neck cancer drug Erbitux (cetuximab) does not represent value for money. The drug is marketed by Germany’s Merck KGaA (MRK: DE), which has marketing rights outside of the USA and Canada.

The NICE, the medicines cost-effectiveness watchdog for England and Wales, originally published guidance in 2009 which said cetuximab was not cost effective for treating recurrent and/or metastatic squamous cell cancer of the head and neck.It was later made available through the Cancer Drug Fund (CDF). The NICE is reconsidering cetuximab as part of its program to appraise drugs that are currently available on the CDF.

As part of this reappraisal Merck presented further evidence which was not included in its original submission and reduced the number of patients who would be eligible for the drug to those with mouth cancer. A discount to the price of cetuximab also means that it now costs less than at the time of the original appraisal.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK